Guggenheim Reiterates Buy Rating for Merus (NASDAQ:MRUS)

Merus (NASDAQ:MRUS)‘s stock had its “buy” rating reaffirmed by equities research analysts at Guggenheim in a report issued on Wednesday,Benzinga reports.

Other equities analysts also recently issued research reports about the stock. Citigroup boosted their price objective on shares of Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price target on shares of Merus in a research report on Monday, December 9th. The Goldman Sachs Group started coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective for the company. Wells Fargo & Company initiated coverage on Merus in a research note on Friday, February 7th. They issued an “overweight” rating and a $91.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $85.00 price target on shares of Merus in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $85.92.

Merus Stock Performance

NASDAQ MRUS opened at $40.30 on Wednesday. Merus has a one year low of $37.77 and a one year high of $61.61. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -10.20 and a beta of 1.11. The company’s 50-day simple moving average is $41.71 and its two-hundred day simple moving average is $47.37.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in shares of Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 300 shares during the last quarter. Avior Wealth Management LLC purchased a new stake in Merus during the 4th quarter valued at about $76,000. nVerses Capital LLC increased its holdings in shares of Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 1,500 shares during the period. US Bancorp DE purchased a new position in shares of Merus in the third quarter worth about $103,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 489 shares during the period. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.